Heidelberg, Baden-Wurttemberg, Germany The leading representative office of defined VC is situated in the Heidelberg. The venture was found in Europe in Germany.
Speaking about the real fund results, this VC is 11 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this EMBL Ventures performs on 4 percentage points less the average number of lead investments. The fund is constantly included in less than 2 deals per year. The high activity for fund was in 2013. The increased amount of exits for fund were in 2017. Deals in the range of 10 - 50 millions dollars are the general things for fund.
We also calculated 5 valuable employees in our database.
Among the most popular fund investment industries, there are Biopharma, Medical. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. The fund has no exact preference in a number of founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager. For fund there is a match between the location of its establishment and the land of its numerous investments - Germany. Among the most popular portfolio startups of the fund, we may highlight Vasopharm, Opsona, Crescendo Biologics.
The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the EMBL Ventures, startups are often financed by Sofinnova Partners, Seroba Life Sciences, Inventages Venture Capital Investment Inc.. The meaningful sponsors for the fund in investment in the same round are Andera Partners, Wellington Partners, Sunstone Life Science Ventures. In the next rounds fund is usually obtained by Wellington Partners, dievini Hopp Biotech Holding, Entrepreneurs Fund.
Related Funds
Funds with similar focus
| Fund Name | Location |
| B-Style | Japan, Yamanashi, Yamanashi Prefecture |
| Blockchange Ventures | New York, New York, United States |
| CFV Ventures | Charlotte, North Carolina, United States |
| Dalma Capital | Dubai, United Arab Emirates |
| Estiriac SL | - |
| Gernot Langes-Swarovski Group | - |
| Headway Capital Partners | England, London, United Kingdom |
| Memorial Hermann Hospital | Houston, Texas, United States |
| Myer Family Investments | Australia, Melbourne, Victoria |
| NewSpring Capital | Pennsylvania, Radnor, United States |
| Ningbo Gaofa Automotive Control System | China, Ningbo Shi, Zhejiang |
| One Media | Hokkaido Prefecture, Japan, Meguro |
| Pine Brook Partners | New York, New York, United States |
| Tenfore Holdings | New York, New York, United States |
| TQS Advisors | - |
| VCO Ventures | Germany, Hamburg |
| Wanrong Capital | Beijing, Beijing, China |
| Weigao Group | China, Shandong, Weihai |
| Yunfeng Touzi | China, Hangzhou, Zhejiang |
Discover 4 more decision makers Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Topas Therapeutics | $21M | 29 Jul 2021 | Germany, Baden-Württemberg, Germany | ||
Topas Therapeutics | $25M | 19 Oct 2020 | Germany, Baden-Württemberg | ||
Crescendo Biologics | $70M | 30 Apr 2018 | Cambridge, England, United Kingdom | ||
Luxendo | $9M | 12 Jan 2017 | Baden-Württemberg | ||
Allecra Therapeutics | $25M | 15 Jun 2016 | Baden-Württemberg | ||
Topas Therapeutics | $16M | 22 Mar 2016 | Germany, Baden-Württemberg, Germany | ||
Luxendo | $7M | 14 Oct 2015 | Heidelberg, Baden-Württemberg, Germany | ||
Vira Therapeutics | $4M | 24 Jun 2015 | Innsbruck, Tyrol, Austria | ||
ImevaX | $8M | 28 Oct 2014 | Bavaria |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Topas Therapeutics | $21M | 29 Jul 2021 | Germany, Baden-Württemberg, Germany | ||
Topas Therapeutics | $25M | 19 Oct 2020 | Germany, Baden-Württemberg | ||
Crescendo Biologics | $70M | 30 Apr 2018 | Cambridge, England, United Kingdom | ||
Luxendo | $9M | 12 Jan 2017 | Baden-Württemberg | ||
Allecra Therapeutics | $25M | 15 Jun 2016 | Baden-Württemberg | ||
Topas Therapeutics | $16M | 22 Mar 2016 | Germany, Baden-Württemberg, Germany | ||
Luxendo | $7M | 14 Oct 2015 | Heidelberg, Baden-Württemberg, Germany | ||
Vira Therapeutics | $4M | 24 Jun 2015 | Innsbruck, Tyrol, Austria | ||
ImevaX | $8M | 28 Oct 2014 | Bavaria |
